Adventures in Capitalism: Outcry Over EpiPen Prices Hasn’t Made Them Lower

Mylan has an effective monopoly on a lifesaving product, which has allowed its leaders to see public outrage as a tax they must pay.

from NYT > Health http://ift.tt/2qQu87u
via health&fitness